PatientFi

It's the moment after the price.

A patient sits in a consult room. The doctor has just named a number. There's a pause - the expensive kind. Then someone slides a tablet across the desk and says, "Let's see what you're approved for." Thirty seconds later, the number has a monthly shape, and the conversation keeps going.

That pause is the entire business. PatientFi lives inside it. The company builds the financing layer that sits at the checkout of elective medicine - plastic surgery, dermatology, dentistry, LASIK, fertility, med spas - and converts a single intimidating figure into a plan a person can actually say yes to. It is, in the company's own words, "the friendly way to pay." Friendly is doing a lot of work in that sentence, and it earns it.

Headquartered in Irvine, California, with roughly 130 employees, PatientFi is not a clinic and not a bank in the way you picture one. It is the quiet infrastructure that practices switch on so that fewer patients walk out the door over money. The pitch to the patient: apply in under thirty seconds, find out instantly, and - the part people don't believe at first - without denting your credit score.

Insurance covers the necessary. The rest is on you.

Here is the uncomfortable truth elective medicine runs on: the treatments people most want are often the ones nobody else will pay for. Insurance is built for the medically necessary, which means the cosmetic, the corrective, the fertility journey, the smile you've wanted since high school - those land squarely on the patient's own card. And the prices are not small.

So practices lost people. Not because the patient didn't want the procedure, but because the lump sum arrived all at once and the financing on offer was clunky, slow, or quietly hostile. The old model asked you to fill out a hard credit application at the front desk - the kind that dings your score just for being curious - and then wait. Curiosity, it turned out, had a cost. Most people declined to be curious.

The result was a strange standoff. Patients wanted care. Practices wanted patients. Money sat in the middle like an awkward dinner guest. Somebody had to make the introduction less painful.

Three founders, one wager: make the awkward part disappear.

In 2017, Todd Watts, Rob Rosenblum and Michael Botta bet that the problem wasn't demand - it was friction. Watts had spent years where the money lives: investment banking at J.P. Morgan, an MBA from Yale, the full Wall Street resume. He left it to build software for a doctor's checkout screen. People found that slightly absurd. The founders did not.

Their wager was specific. If you could make the financing decision instant, soft on credit, and embedded right where the price is delivered, the pause after the number would stop being a dead end. The patient would stay in the chair. The practice would keep the appointment. And the financing - the thing everyone had been treating as a necessary evil - could actually feel, of all things, friendly.

It was a fintech bet dressed in a bedside manner. Watts would later be named EY Entrepreneur Of The Year 2024 for the Pacific Southwest - validation that the absurd idea had grown teeth.

A soft credit check that lets you peek without paying for it.

What PatientFi actually ships is a device-agnostic platform with two faces. For the patient: a thirty-second application, a soft credit check that leaves the score untouched, an instant decision, and a monthly payment they can see before they commit. For the practice: a dashboard for applications, approvals, payment tracking, revenue reporting, and marketing tools - all of it tuned to lift acceptance rates without making the front desk learn a new religion.

The clever part is the breadth. PatientFi doesn't pick one niche and camp there. It finances plastic surgery and dermatology, dentistry and orthodontics, ophthalmology and LASIK and cataract surgery, fertility treatment, audiology, med spas and rehab. Wherever insurance stops, PatientFi tends to start.

Investors kept raising the number.

Skeptics ask a fair question: is this a real business or a nice idea with a soft credit check? The funding curve is one answer. Across roughly seven rounds, backers - Questa Capital, Patriot Financial Partners, Montreux Growth Partners, Curql Collective - put in about $115 million. The headline rounds tell the trajectory plainly.

The other answer is who's plugging in. PatientFi doesn't just sign practices - it embeds into the tools practices already live in. Native integrations with Aesthetic Record and 4D EMR mean financing rides inside the existing checkout. Partnerships with Galderma and Allergan Aesthetics connect it to the products patients are buying. An EngagedMD partnership extends it into fertility. Recognition followed: Deloitte's Technology Fast 500, the Inc. 5000, and an EY award for its CEO.

Two sides of the same friendly counter.

Access, with the financial stress turned down.

Strip away the fintech vocabulary and PatientFi is making a claim about fairness. The treatments that change how people feel about themselves - their face, their smile, their sight, their shot at a family - shouldn't be gated by whether someone can absorb a four- or five-figure bill in a single afternoon. Spreading the cost isn't a gimmick; it's the difference between a yes and a no.

That's also why the "friendly" framing isn't just marketing gloss. The competition in this category - CareCredit, Cherry, Sunbit, Affirm and others - largely competes on the same axis: how little does it hurt to say yes. PatientFi's whole posture is that the financing should feel like part of the care, not a tollbooth bolted onto the exit.

Back to the pause after the price.

Elective healthcare keeps growing - aesthetics, vision correction, fertility, dental are all expanding markets, and none of them are waiting on insurance to come around. As they grow, the awkward moment after the number gets repeated millions of times a year. Whoever owns that moment owns a real piece of how care gets paid for.

PatientFi's plan for tomorrow is more of what's already working: deeper integrations into the software practices use, more specialties, more reach into the places people pay out of pocket. The less the financing feels like a separate step, the more the pause disappears entirely.

Which returns us to that consult room. The doctor names the number. The pause arrives. But now the tablet slides over, the answer comes back in thirty seconds, and the score stays untouched. The expensive silence got shorter. For a company built entirely inside that silence, making it shorter is the whole point - and, so far, the market keeps signing off on the work.